Ocular surface disease and glaucoma

References

• Anwar Z, Wellik SR, Galor A. Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol. 2013;24:136–143.
   PubMed Web of Science ®Google Scholar
• Kaštelan S, Tomić M, Metež Soldo K, et al. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328.
   PubMed Web of Science ®Google Scholar
• Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131–2135.
   PubMedGoogle Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–726.
   PubMed Web of Science ®Google Scholar
• Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60–64.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. The Italian version of the glaucoma symptom scale questionnaire: translation, validation, and reliability. J Glaucoma. 2013;22:44–51.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109–115.
   PubMed Web of Science ®Google Scholar
• Radcliffe NM. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014;8:2541–2549.
   PubMedGoogle Scholar
• Oguz H. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1003; authorreply 1003–4.
   PubMed Web of Science ®Google Scholar
• Pinheiro R, Panfil C, Schrage N, et al. The impact of glaucoma medications on corneal wound healing. J Glaucoma. 2016;25:122–127.
   PubMed Web of Science ®Google Scholar
• Helin M, Rönkkö S, Puustjärvi T, et al. Conjunctival inflammatory cells and their predictive role for deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma. J Glaucoma. 2011;20:172–178.
   PubMed Web of Science ®Google Scholar
• Liu X, Yu F-F, Zhong Y-M, et al. Therapeutic effects of sodium hyaluronate on ocular surface damage induced by benzalkonium chloride preserved anti-glaucoma medications. Chin Med J (Engl). 2015;128:2444–2449.
   PubMed Web of Science ®Google Scholar
• Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol. 2007;91:29–32.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Teranishi S, Sagara T, et al. Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial punctate keratitis. J Glaucoma. 2015;24:e145–e150.
   PubMed Web of Science ®Google Scholar
• Costa VP, Marcon IM, Galvão FRP, et al. The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension. Arq Bras Oftalmol. 2013;76:221–225.
   PubMed Web of Science ®Google Scholar
• Caprioli J, Df G-H, International GTT. A critical reevaluation of current glaucoma management: international glaucoma think tank, July 27-29, 2006, Taormina, Sicily. Ophthalmology. 2007;114:S1–S41.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1–9.e2.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36:391–398.
   PubMed Web of Science ®Google Scholar
• Actis AG, Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: a review. Open Ophthalmol J. 2014;8:67–72.
   PubMedGoogle Scholar
• Goldberg I, Graham SL, Crowston JG, et al. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Experiment Ophthalmol. 2015;43:214–220.
   PubMed Web of Science ®Google Scholar
• Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23:56–60.
   PubMed Web of Science ®Google Scholar
• Katz G, Springs CL, Craven ER, et al. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol. 2010;4:1253–1261.
   PubMedGoogle Scholar
• Saade CE, Lari HB, Berezina TL, et al. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. Can J Ophthalmol. 2015;50:132–136.
   PubMed Web of Science ®Google Scholar
• Ali FS, Akpek EK. Glaucoma and dry eye. Ophthalmology. 2009;116:1232.
   PubMed Web of Science ®Google Scholar
• Cvenkel B, Š Š, Srebotnik Kirbiš I, et al. Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma. Clin Ophthalmol. 2015;9:625–631.
   PubMed Web of Science ®Google Scholar
• Asbell PA, Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocul Surf. 2005;3:27–40.
   PubMed Web of Science ®Google Scholar
• Chia E-M, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2003;31:229–232.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–1268.
   PubMed Web of Science ®Google Scholar
• Kocabeyoglu S, Mocan MC, Irkec M, et al. Conjunctivochalasis as a contributing factor for the development of ocular surface disease in medically treated glaucoma patients. J Glaucoma. 2014;23:333–336.
   PubMed Web of Science ®Google Scholar
• Lu VH, Goldberg I, Lu CY. Use of glaucoma medications: state of the science and directions for observational research. Am J Ophthalmol. 2010;150:569–574.e9.
   PubMed Web of Science ®Google Scholar
• Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441–446.
   PubMedGoogle Scholar
• Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12:480–485.
   PubMed Web of Science ®Google Scholar
• Lemij HG, Hoevenaars JG, Van Der Windt C, et al. Patient satisfaction with glaucoma therapy: reality or myth. Clin Ophthalmol. 2015;9:785–793.
   PubMed Web of Science ®Google Scholar
• Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic Outcome with respect to Dry Eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593–1601.
   PubMed Web of Science ®Google Scholar
• Saini M, Dhiman R, Dada T, et al. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015;29:808–814.
   PubMed Web of Science ®Google Scholar
• Tsai JH, Derby E, Holland EJ, et al. Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea. 2006;25:530–532.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486–490.
   PubMed Web of Science ®Google Scholar
• Mathews PM, Ramulu PY, Friedman DS, et al. Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology. 2013;120:2241–2248.
   PubMed Web of Science ®Google Scholar
• Schein OD, Muñoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723–728.
   PubMed Web of Science ®Google Scholar
• McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114–1119.
   PubMed Web of Science ®Google Scholar
• Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110:1096–1101.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–423.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618–621.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Ruangvaravate N, Tesavibul N, et al. Effect of 0.3% hydroxypropyl methylcellulose/dextran versus 0.18% sodium hyaluronate in the treatment of ocular surface disease in glaucoma patients: a randomized, double-blind, and controlled study. J Ocul Pharmacol Ther. 2015;31:323–329.
   PubMed Web of Science ®Google Scholar
• Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28:267–282.
   PubMed Web of Science ®Google Scholar
• Zhu W, Kong X, Xu J, et al. Effects of long-term antiglaucoma eye drops on conjunctival structures: an in vivo confocal microscopy study. J Ophthalmol. 2015;2015:165475.
   PubMedGoogle Scholar
• Mastropasqua R, Agnifili L, Fasanella V, et al. Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Invest Ophthalmol Vis Sci. 2015;56:2050–2058.
   PubMed Web of Science ®Google Scholar
• Kocabeyoglu S, Mocan MC, Irkec M. The influence of glaucoma medications on ocular surface disease in primary open-angle glaucoma patients with and without conjunctivochalasis.[letter]. Acta Ophthalmol. 2014;92(7):e592–e593.
   PubMed Web of Science ®Google Scholar
• Abegão Pinto L, Vandewalle E, Gerlier L, et al. Improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combination. Ophthalmologica. 2014;231:166–171.
   PubMed Web of Science ®Google Scholar
• Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther. 2014;30:163–169.
   PubMed Web of Science ®Google Scholar
• Pouyeh B, Viteri E, Feuer W, et al. Impact of ocular surface symptoms on quality of life in a United States veterans affairs population. Am J Ophthalmol. 2012;153:1061–66.e3.
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–496.
   PubMed Web of Science ®Google Scholar
• De Kaspar HM, Kreidl KO, Singh K, et al. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma. 2004;13:507–509.
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–735.
   PubMed Web of Science ®Google Scholar
• Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma. 2001;10:483–486.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111:2186–2192.
   PubMed Web of Science ®Google Scholar
• Liang H, Pauly A, Riancho L, et al. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol. 2011;95:869–875.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv Ther. 2009;26:970–975.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98–103.
   PubMed Web of Science ®Google Scholar
• Koh SW, Coll TJ, Rose L, et al. Antiglaucoma eye drop pulses–increased interleukin-6 secretion by Tenon’s capsule fibroblast cultures. J Glaucoma. 2004;13:200–209.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Huang Y-L, Ju J-P, et al. Altered transcripts expression of matrix metalloproteinases and their tissue inhibitors in tenon capsule of patients with glaucoma. J Glaucoma. 2004;13:486–491.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu D, Li J. Latanoprost-induced cytokine and chemokine release from human Tenon’s capsule fibroblasts: role of MAPK and NF-κB signaling pathways. J Glaucoma. 2015;24:635–641.
   PubMed Web of Science ®Google Scholar
• Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17:217–222.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Jenkins JN, et al. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J Glaucoma. 2003;12:475–479.
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
   PubMed Web of Science ®Google Scholar
• Levrat F, Pisella PJ, Baudouin C. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe]. J Fr Ophtalmol. 1999;22:186–191.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–336.
   PubMed Web of Science ®Google Scholar
• Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10:237–249.
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Felipe Crosta DP, Soares CP, et al. Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment. J Glaucoma. 2009;18:197–200.
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436.
   PubMed Web of Science ®Google Scholar